Rakesh, Kumar (2021) In Memoriam: Jos�e Baselga’s Journey in Cancer Medicine. Clinical cancer research, 27 (12). pp. 3499-3502. ISSN 1557-326

Text In memoriam.pdf Restricted to Registered users only Download (262Kb) | Request a copy

Abstract

Breast cancer continues to register one of the most common incidence and deaths among female cancers. However, during the last three decades, breast cancer treatment benefited from a sea-change for specific subtypes. These successes led to increases in the period of cancer remission, reduced therapeutic resistance, inhibition of drug toxicity, and resulting in almost life-long remission in some cases. These gains in prolonging the life of patients with breast cancer are largely attributed to targeted therapies and ever-evolving combination modalities by the bold effort of basic and clinical scientists and practicing oncologists (1–3). The records of these advances in clinical cancer research and combination targeted therapeutics would be sketchy in the absence of untiring and transforming scientific effort of our colleague Dr. Jos�e Baselga, who died on March 21, 2021 in Cerdanya, Spain. To illustrate a fulfilling career in cancer medicine and his contributions to clinical cancer research, here we will attempt to bring out a few, less-known features of Jos�e’s journey in clinical cancer research and treatment, and how these advances shaped the field of combination cancer therapeutics with a direct impact on the life of patients with breast cancer. We will begin with Jos�e’s early formative years and decisive turning point(s) along his expedition in cancer medicine and accentuate how Jos�e maintained a two-way flow of meaningful scientific questions between the laboratory and clinical settings, with a singular motive to improve the treatment of breast cancer.

Item Type:	Article
Subjects:	Cancer Research
Depositing User:	Central Library RGCB
Date Deposited:	17 Feb 2022 07:33
Last Modified:	17 Feb 2022 07:33
URI:	http://rgcb.sciencecentral.in/id/eprint/1121

Actions (login required)

View Item